World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
104
Citations
59579
World Ranking
6907
National Ranking
3641

Mario A. Eisenberger publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Mario A. Eisenberger sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 567 publications — 68th percentile

68% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Mario A. Eisenberger D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Mario A. Eisenberger sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 104 D-Index — 66th percentile

66% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Mario A. Eisenberger is affiliated with Johns Hopkins University in the United States. Their research primarily centers on medicine, with a focus on pulmonary and respiratory medicine, radiology, nuclear medicine and imaging, oncology, endocrinology, diabetes and metabolism, and cancer research.

The scientist's work covers several main topics, notably:

  • Prostate Cancer Treatment and Research
  • Radiopharmaceutical Chemistry and Applications
  • Prostate Cancer Diagnosis and Treatment
  • Cancer Treatment and Pharmacology
  • Hormonal and reproductive studies
  • Cancer Immunotherapy and Biomarkers
  • Multiple Myeloma Research and Treatments

Mario A. Eisenberger's publication record includes numerous articles published in significant oncology and medical journals. Frequent publication venues include:

  • Journal of Clinical Oncology
  • Annals of Oncology
  • The Prostate
  • International Journal of Radiation Oncology*Biology*Physics
  • European Urology

Coauthor collaborations have been a notable aspect of their research output. Frequent co-authors include:

  • Mark C. Markowski
  • Emmanuel S. Antonarakis
  • Michael A. Carducci
  • Channing J. Paller
  • Samuel R. Denmeade

Recent papers authored or co-authored by Mario A. Eisenberger demonstrate engagement in clinical oncology research related to prostate cancer. Selected recent publications are:

  • Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer, 2020, JAMA Oncology
  • TRANSFORMER: A Randomized Phase II Study Comparing Bipolar Androgen Therapy Versus Enzalutamide in Asymptomatic Men With Castration-Resistant Metastatic Prostate Cancer, 2021, Journal of Clinical Oncology
  • Metastasis-directed Therapy Prolongs Efficacy of Systemic Therapy and Improves Clinical Outcomes in Oligoprogressive Castration-resistant Prostate Cancer, 2020, European Urology Oncology
  • A Multicohort Open-label Phase II Trial of Bipolar Androgen Therapy in Men with Metastatic Castration-resistant Prostate Cancer (RESTORE): A Comparison of Post-abiraterone Versus Post-enzalutamide Cohorts, 2020, European Urology
  • Nivolumab plus ipilimumab, with or without enzalutamide, in AR-V7-expressing metastatic castration-resistant prostate cancer: A phase-2 nonrandomized clinical trial, 2021, The Prostate

Best Publications

  • Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer

    Ian F. Tannock;Ronald de Wit;William R. Berry;Jozsef Horti

  • Natural history of progression after PSA elevation following radical prostatectomy.

    Charles R. Pound;Alan W. Partin;Mario A. Eisenberger;Daniel W. Chan

  • AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer.

    Emmanuel S. Antonarakis;Changxue Lu;Hao Wang;Brandon Luber

  • Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer

    Christopher J. Sweeney;Yu Hui Chen;Michael Carducci;Glenn Liu

  • Risk of Prostate Cancer-Specific Mortality Following Biochemical Recurrence After Radical Prostatectomy

    Stephen J. Freedland;Elizabeth B. Humphreys;Leslie A. Mangold;Mario Eisenberger

  • Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.

    Howard I. Scher;Susan Halabi;Ian Tannock;Michael Morris

  • A controlled trial of leuprolide with and without flutamide in prostatic carcinoma.

    E D Crawford;M A Eisenberger;D G McLeod;J T Spaulding

  • Docetaxel Plus Prednisone or Mitoxantrone Plus Prednisone for Advanced Prostate Cancer: Updated Survival in the TAX 327 Study

    Dominik R. Berthold;Gregory R. Pond;Freidele Soban;Ronald de Wit

  • Eligibility and Response Guidelines for Phase II Clinical Trials in Androgen-Independent Prostate Cancer: Recommendations From the Prostate-Specific Antigen Working Group

    Glenn J. Bubley;Michael Carducci;William Dahut;Nancy Dawson

  • Bilateral orchiectomy with or without flutamide for metastatic prostate cancer

    Mario A. Eisenberger;Brent A. Blumenstein;E. David Crawford;Gary Miller

  • Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial

    Christos E. Kyriakopoulos;Yu Hui Chen;Michael A. Carducci;Glenn Liu

  • Cancer-Related Fatigue, Version 2.2015

    Ann Malone Berger;Kathi Mooney;Amy Alvarez-Perez;William S. Breitbart

  • Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomized Clinical Trial

    Ryan Phillips;William Yue Shi;Matthew Deek;Noura Radwan

  • Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate.

    Joel B. Nelson;Sean P. Hedican;Daniel J. George;A. H. Reddi

  • Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer

    Wennuan Liu;Sari Laitinen;Sofia Khan;Mauno Vihinen

  • NCCN Practice Guidelines for Cancer-Related Fatigue.

    V. Mock;A. Atkinson;A. Barsevick;D. Cella

  • Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer

    Emmanuel S. Antonarakis;Changxue Lu;Brandon Luber;Hao Wang

  • Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men With Metastatic Castration-Resistant Prostate Cancer Treated With First- and Second-Line Abiraterone and Enzalutamide

    Emmanuel S. Antonarakis;Changxue Lu;Brandon Luber;Hao Wang

  • Initial Evaluation of [18F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer

    Zsolt Szabo;Esther Mena;Steven P. Rowe;Donika Plyku

  • Long-term effects of androgen deprivation therapy in prostate cancer patients

    Shehzad Basaria;John Lieb;Alice M. Tang;Theodore DeWeese

Frequent Co-Authors

Michael A. Carducci
Michael A. Carducci Johns Hopkins University
Emmanuel S. Antonarakis
Emmanuel S. Antonarakis University of Minnesota
Alan W. Partin
Alan W. Partin Johns Hopkins University School of Medicine
Roberto Pili
Roberto Pili University at Buffalo, State University of New York
Kenneth J. Pienta
Kenneth J. Pienta Johns Hopkins University School of Medicine
Phuoc T. Tran
Phuoc T. Tran Johns Hopkins University School of Medicine
Patrick C. Walsh
Patrick C. Walsh Johns Hopkins University
Maha Hussain
Maha Hussain Northwestern University
Michael J. Morris
Michael J. Morris Memorial Sloan Kettering Cancer Center
E. David Crawford
E. David Crawford University of California, San Diego

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring medical careers in the USA isn’t limited to traditional MD programs. Many students consider related online degrees as a flexible, cost-effective route to healthcare professions. For example, those seeking practical training may ask, what is the cheapest online college for nursing? Affordable nursing degrees can pave the way to rewarding roles in patient care.

For working nurses looking to advance, cheap rn to bsn programs offer a way to earn bachelor's qualifications at a lower cost, often entirely online. Ambitious students can also explore advanced degrees, such as an online nursing doctorate, which prepares nurses for leadership and research positions.

Even career changers can join the health field through entry level msn programs online. These pathways help students with non-nursing backgrounds quickly transition to high-demand medical roles. With a broad range of online options, it’s easier than ever to launch or advance your healthcare career in the United States.

Best Scientists Citing Mario A. Eisenberger

Trending Scientists